Doximity Inc. logo

Doximity Inc. (DOCS)

Market Closed
22 Jul, 20:00
NYSE NYSE
$
59. 38
-0.87
-1.44%
Pre Market
$
59. 25
-0.13 -0.22%
11.32B Market Cap
51.81 P/E Ratio
0% Div Yield
1,589,600 Volume
0.86 Eps
$ 60.25
Previous Close
Day Range
58.91 60.66
Year Range
25 85.21
Want to track DOCS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 14 days
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year

Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year

Dr Martens PLC (LSE:DOCS) reported a 10% drop in group revenue to £787.6 million for the year ended 30 March 2025, amidst a marketing 'reset'. Adjusted profit before tax fell to £34.1 million from £97.2 million, the boot brand said in the results statement.

Proactiveinvestors | 1 month ago
The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks

The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks

His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach.

247wallst | 1 month ago
Doximity Rides on Telehealth Demand: Will This Drive Sales Further?

Doximity Rides on Telehealth Demand: Will This Drive Sales Further?

DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.

Zacks | 1 month ago
Dr Martens interims a first test for new CEO after shares stumble to all-time low

Dr Martens interims a first test for new CEO after shares stumble to all-time low

Dr Martens PLC (LSE:DOCS) shares stumbled to a new all-time low below 50p last month after the US tariff announcement, but have been tiptoeing higher in the run-up to interim results due next Thursday, 5 June.  Back in January, the boot-maker flagged "good progress" in its turnaround after revenue ticked up 3% on a constant currency basis during the third quarter, aided by stronger American and Asia Pacific sales, offsetting a decline in Europe due to strong promotional activity from rivals in December.

Proactiveinvestors | 1 month ago
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up

Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up

DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.

Zacks | 2 months ago
Doximity, Inc. (DOCS) Q4 2025 Earnings Call Transcript

Doximity, Inc. (DOCS) Q4 2025 Earnings Call Transcript

Doximity, Inc. (NYSE:DOCS ) Q4 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Perry Gold - Head of IR Jeff Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Ryan MacDonald - Needham Jared Haase - William Blair Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Ann Samuel - JPMorgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Steven Veliquette - Mizuho Securities Jeff Garro - Stephens David Roman - Goldman Sachs Jailendra Singh - Truist Craig Hettenbach - Morgan Stanley Operator Good day, everyone, and welcome to the Doximity Q4 2025 Earnings Call. At this time, I will hand the call over to Perry Gold, Head of IR.

Seekingalpha | 2 months ago
Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates

Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates

Doximity (DOCS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.25 per share a year ago.

Zacks | 2 months ago
Doximity Stock Drops 20% After Outlook Disappoints

Doximity Stock Drops 20% After Outlook Disappoints

Shares of Doximity plummeted late Thursday after the telehealth software company dished out a disappointing outlook.

Investopedia | 2 months ago
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.

Zacks | 2 months ago
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note

Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note

In the closing of the recent trading day, Doximity (DOCS) stood at $56.65, denoting a +0.64% change from the preceding trading day.

Zacks | 2 months ago
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?

Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment?

Zacks | 3 months ago
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know

Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know

Doximity (DOCS) closed at $60.55 in the latest trading session, marking a -1.51% move from the prior day.

Zacks | 3 months ago
Loading...
Load More